Mathias; John Paul
Patent Applications and Registrations
Patent applications and USPTO patent grants for Mathias; John Paul.The latest application filed is for "pyrrolopyrimidines as cftr potentiators".
Company Profile
19.27.35
- Mathias; John Paul - Concord MA
- Mathias; John Paul - Sandwich GB
- Mathias; John Paul - Ashford GB
- Mathias; John Paul - Kent GB
Patent Activity
| Patent | Date |
|---|---|
| Pyrrolopyrimidines as CFTR Potentiators App 20210171534 - Strohbach; Joseph Walter ; et al. | 2021-06-10 |
| Bicyclic-Fused Heteroaryl or Aryl Compounds App 20200377511 - Trzupek; John David ; et al. | 2020-12-03 |
| Bicyclic-fused heteroaryl or aryl compounds Grant 10,793,579 - Trzupek , et al. October 6, 2 | 2020-10-06 |
| Bicyclic heteroaryl derivatives as CFTR potentiators Grant 10,766,904 - Strohbach , et al. Sep | 2020-09-08 |
| Pyrrolopyrimidines As Cftr Potentiators App 20200017512 - Strohbach; Joseph Walter ; et al. | 2020-01-16 |
| Pyrrolopyrimidines as CFTR potentiators Grant 10,494,374 - Strohbach , et al. De | 2019-12-03 |
| Bicyclic Heteroaryl Derivatives As Cftr Potentiators App 20190330219 - Strohbach; Joseph Walter ; et al. | 2019-10-31 |
| Novel Heterocyclic Compounds As Inhibitors Of Vanin-1 Enzyme App 20190292157 - Casimiro-Garcia; Agustin ; et al. | 2019-09-26 |
| Bicyclic-Fused Heteroaryl or Aryl Compounds App 20190270751 - Trzupek; John David ; et al. | 2019-09-05 |
| Bicyclic heteroaryl derivatives as CFTR potentiators Grant 10,377,762 - Strohbach , et al. A | 2019-08-13 |
| Pyrrolopyrimidines As Cftr Potentiators App 20190225621 - Strohbach; Joseph Walter ; et al. | 2019-07-25 |
| Bicyclic-fused heteroaryl or aryl compounds Grant 10,329,302 - Trzupek , et al. | 2019-06-25 |
| Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Grant 10,316,018 - Lee , et al. | 2019-06-11 |
| Heterocyclic compounds as inhibitors of Vanin-1 enzyme Grant 10,308,615 - Casimiro-Garcia , et al. | 2019-06-04 |
| Pyrrolopyrimidines as CFTR potentiators Grant 10,301,315 - Strohbach , et al. | 2019-05-28 |
| Bicyclic-fused Heteroaryl Or Aryl Compounds As Irak4 Modulators App 20190092750 - LEE; KATHERINE LIN ; et al. | 2019-03-28 |
| Bicyclic heteroaryl derivatives as CFTR potentiators Grant 10,208,053 - Strohbach , et al. Feb | 2019-02-19 |
| Bicyclic Heteroaryl Derivatives As Cftr Potentiators App 20190016727 - Strohbach; Joseph Walter ; et al. | 2019-01-17 |
| Bicyclic Heteroaryl Derivatives As Cftr Potentiators App 20190016728 - Strohbach; Joseph Walter ; et al. | 2019-01-17 |
| Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Grant 10,174,000 - Lee , et al. J | 2019-01-08 |
| Bicyclic heteroaryl derivatives as CFTR potentiators Grant 10,131,670 - Strohbach , et al. November 20, 2 | 2018-11-20 |
| Bicyclic-fused Heteroaryl Or Aryl Compounds As Irak4 Modulators App 20180244646 - LEE; KATHERINE LIN ; et al. | 2018-08-30 |
| Bicyclic Heteroaryl Derivatives As Cftr Potentiators App 20180170938 - Strohbach; Joseph Walter ; et al. | 2018-06-21 |
| Novel Heterocyclic Compounds As Inhibitors Of Vanin-1 Enzyme App 20180148420 - Casimiro-Garcia; Agustin ; et al. | 2018-05-31 |
| Pyrrolopyrimidines As Cftr Potentiators App 20180141954 - Strohbach; Joseph Walter ; et al. | 2018-05-24 |
| Bicyclic-Fused Heteroaryl or Aryl Compounds App 20180127432 - Trzupek; John David ; et al. | 2018-05-10 |
| Bicyclic-fused heteroaryl or aryl compounds Grant 9,879,022 - Trzupek , et al. January 30, 2 | 2018-01-30 |
| Bicyclic-Fused Heteroaryl or Aryl Compounds App 20160347760 - Trzupek; John David ; et al. | 2016-12-01 |
| Bicyclic-fused heteroaryl or aryl compounds Grant 9,458,168 - Trzupek , et al. October 4, 2 | 2016-10-04 |
| Bicyclic-Fused Heteroaryl or Aryl Compounds App 20150284405 - Trzupek; John David ; et al. | 2015-10-08 |
| Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors Grant 8,076,356 - Mathias , et al. December 13, 2 | 2011-12-13 |
| Pharmaceutically Active Compounds App 20100035891 - Bunnage; Mark Edward ; et al. | 2010-02-11 |
| Tetrahydronaphthyridine Derivatives App 20090258861 - Lunn; Graham ; et al. | 2009-10-15 |
| Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors App 20090239899 - Mathias; John Paul ; et al. | 2009-09-24 |
| Tetrahydronaphthyridine derivatives Grant 7,557,121 - Lunn , et al. July 7, 2 | 2009-07-07 |
| Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors Grant 7,511,057 - Mathias , et al. March 31, 2 | 2009-03-31 |
| Compounds App 20090035313 - Barber; Christohper Gordon ; et al. | 2009-02-05 |
| Triazolopyridine Compounds App 20090012079 - Lewthwaite; Russell Andrew ; et al. | 2009-01-08 |
| Process for preparing pharmaceutically active compounds Grant 7,176,311 - Bunnage , et al. February 13, 2 | 2007-02-13 |
| Pharmaceutically Active Compounds App 20060293347 - Bunnage; Mark Edward ; et al. | 2006-12-28 |
| Nicotinamide derivatives useful as PDE4 inhibitors Grant 7,153,870 - Mathias December 26, 2 | 2006-12-26 |
| Nicotinamide derivatives useful as pde4 inhibitors App 20060178408 - Barber; Christopher Gordon ; et al. | 2006-08-10 |
| Nicotinamide derivatives useful as PDE4 inhibitors Grant 7,056,934 - Bunnage , et al. June 6, 2 | 2006-06-06 |
| Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors App 20060035922 - Mathias; John Paul ; et al. | 2006-02-16 |
| Tetrahydronaphthyridine derivatives App 20050256135 - Lunn, Graham ; et al. | 2005-11-17 |
| Quinazolinone compounds useful in therapy Grant 6,936,619 - Blagg , et al. August 30, 2 | 2005-08-30 |
| Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction Grant 6,916,927 - Bunnage , et al. July 12, 2 | 2005-07-12 |
| Compounds App 20050043326 - Barber, Christopher Gordon ; et al. | 2005-02-24 |
| Nicotinamide derivatives useful as PDE4 inhibitors App 20050038033 - Bunnage, Mark Edward ; et al. | 2005-02-17 |
| Nicotinamide derivatives useful as PDE4 inhibitors App 20050026952 - Mathias, John Paul | 2005-02-03 |
| Nicotinamide derivatives useful as PDE4 inhibitors App 20050020626 - Mathias, John Paul | 2005-01-27 |
| Compounds App 20050020611 - Barber, Christopher Gordon ; et al. | 2005-01-27 |
| Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction App 20040180944 - Bunnage, Mark Edward ; et al. | 2004-09-16 |
| Pharmaceutically active compounds App 20040152712 - Bunnage, Mark Edward ; et al. | 2004-08-05 |
| Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'--monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction Grant 6,723,719 - Bunnage , et al. April 20, 2 | 2004-04-20 |
| Compounds useful in therapy App 20040029859 - Blagg, Julian ; et al. | 2004-02-12 |
| Pharmaceutically active compounds Grant 6,677,335 - Bunnage , et al. January 13, 2 | 2004-01-13 |
| Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction Grant 6,670,366 - Bunnage , et al. December 30, 2 | 2003-12-30 |
| Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction Grant 6,458,951 - Bunnage , et al. October 1, 2 | 2002-10-01 |
| Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction Grant 6,333,330 - Bunnage , et al. December 25, 2 | 2001-12-25 |
| Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction App 20010039271 - Bunnage, Mark Edward ; et al. | 2001-11-08 |
| Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction Grant 6,251,904 - Bunnage , et al. June 26, 2 | 2001-06-26 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 